Receptos, Inc.

Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis

Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis

January 27, 2011

First subject dosed in Phase 1 Single Ascending and Multiple Ascending Dose Safety Study

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Enters Into a Cooperative Research and Development Agreement with Walter Reed Army Institute of Research to Evaluate Neuroprotective Drug Compound

Concert Pharmaceuticals Enters Into a Cooperative Research and Development Agreement with Walter Reed Army Institute of Research to Evaluate Neuroprotective Drug Compound

February 2, 2011

Advances Concert’s R&D for Novel Drugs to Treat Seizure-Generating Diseases and Injuries

Pervasis Therapeutics, Inc.

Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence

Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence

January 19, 2011

Bolstered by Landmark Research and Multiple Preclinical Studies, Groundbreaking Therapy Holds Promise to Deliver Safe, Effective Cell Therapy Treatment for Solid Tumors

Joule Unlimited, Inc.

Joule Elects Former White House Chief of Staff John Podesta to Board of Directors

Joule Elects Former White House Chief of Staff John Podesta to Board of Directors

January 18, 2011

Cambridge, Mass. –January 18, 2010 – Joule Unlimited, Inc., pioneer of Liquid Fuel from the Sun™, today announced the election of John Podesta to its board of directors. A veteran of two White House administrations, Mr. Podesta will bring considerable expertise to Joule in the realm of public policy as well as partnering with the public sector.

BG Medicine, Inc.

BG Medicine Announces Nationwide Availability of Galectin-3 Testing Service through LabCorp

BG Medicine Announces Nationwide Availability of Galectin-3 Testing Service through LabCorp

January 18, 2011

WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine announced today that Laboratory Corporation of America® Holdings (LabCorp®)now offers galectin-3 testing services using the BGM Galectin-3 test for heart failure. The BGM Galectin-3 test was cleared by the FDA in November 2010 as an aid in assessing the prognosis of patients with chronic heart failure. Elevated galectin-3 levels are associated with an inherently progressive form of heart failure that is associated with an increased risk of hospitalization or death.

Mascoma Corporation

Mascoma, Frontier Renewable Resources and Valero Ink Deal to Develop Commercial Cellulosic Ethanol Biorefinery

Mascoma, Frontier Renewable Resources and Valero Ink Deal to Develop Commercial Cellulosic Ethanol Biorefinery

January 13, 2011

Valero invests in Mascoma and signs a letter of intent to help pave way for Kinross, Michiganbased biorefinery.

Mascoma Corporation

Valero to Invest in Ethanol Plant

Valero to Invest in Ethanol Plant

January 13, 2011

The Wall Street Journal previewed the recently announced agreement to between Flagship portfolio company Mascoma and Valero Energy Corp., citing it as a sign of the maturing cellulosic-ethanol technology and market.
 

Selventa

Selventa Launches Software Product Suites for Enhanced Analytics

Selventa Launches Software Product Suites for Enhanced Analytics

January 5, 2011

CAMBRIDGE, Mass. – January 5, 2010 – SelventaTM, which evolved from Genstruct®, Inc. today announced the availability of the latest release of their high-performance analytical software tools. Selventa’s Hypothesis Investigation Suite and the Model Investigation Suite contain an interoperable set of applications that support integrated workflows for generating and investigating key biological mechanisms derived from large volumes of experimental data.

Selventa

Selventa Names David de Graaf as President and Chief Executive Officer

Selventa Names David de Graaf as President and Chief Executive Officer

December 8, 2010

CAMBRIDGE, Mass. – December 8, 2010 – SelventaTM, which evolved from Genstruct®, Inc. announced today that David de Graaf, Ph.D. has been appointed President and Chief Executive Officer (CEO) effective immediately. Dr. de Graaf brings significant scientific and business experience in the biotechnology and pharmaceutical industries. He assumes this leadership role from his most current position as Chief Scientific Officer at Selventa. Dr.

Resolvyx Pharmaceuticals, Inc.

Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology

Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology

October 26, 2010

Celtic Therapeutics to Progress RX-10045 for Dry Eye Syndrome through Phase III Clinical Development